Most people who make the transition to maintenance haemodialysis (HD) therapy are treated with a fixed dose of thrice-weekly HD (3HD/week) regimen without consideration of their residual kidney function (RKF). The RKF provides an effective and naturally continuous clearance of both small and middle molecules, plays a major role in metabolic homeostasis, nutritional status and cardiovascular health, and aids in fluid management. The RKF is associated with better patient survival and greater healthrelated quality of life. Its preservation is instrumental to the prescription of incremental (1HD/week to 2HD/week) HD. The recently heightened interest in incremental HD has been hindered by the current limitations of the urea kinetic model (UKM), which tend to overestimate the needed dialysis dose in the presence of a substantial RKF. A recent paper by Casino and Basile suggested a variable target model (VTM), which gives more clinical weight to the RKF and allows less frequent HD treatments at lower RKF as opposed to the fixed target model, based on the wrong concept of the clinical equivalence between renal and dialysis clearance. A randomized controlled trial (RCT) enrolling incident patients and comparing incremental HD (prescribed according to the VTM) with the standard 3HD/ week schedule and focused on hard outcomes, such as survival and health-related quality of life of patients, is urgently needed. The first step in designing such a study is to compute the 'adequacy lines' and the associated fitting equations necessary for the most appropriate allocation of the patients in the two arms and their correct and safe follow-up. In conclusion, the potentially important clinical and financial implications of the incremental HD render it highly promising and warrant RCTs. The UKM is the keystone for conducting such studies.
A B S T R A C T
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I N T R O D U C T I O N
The majority of dialysis patients are currently treated with a fixed-dose thrice-weekly haemodialysis (HD) (3HD/week) regimen irrespective of whether they are starting dialysis therapy (incident) or have been receiving dialysis for some time (prevalent) and without consideration of their residual kidney function (RKF) [1] . The RKF provides an effective and naturally continuous clearance of both small and middle molecules, plays a major role in metabolic homeostasis, nutritional status and cardiovascular health, and aids in fluid management. The RKF is associated with better patient survival and greater healthrelated quality of life, although these effects may be confounded by patient comorbidities [2] [3] [4] . Although the regulatory agencies might consider the 3HD/week regimen as a 'standard of care' and 'adequate requirement', it is by no means perfect [1] . It has been assumed, until recently, almost as a dogma in the dialysis community [5, 6] . Historically, however, HD started with two treatment sessions per week in the 1960s and 1970s, but by the early 1980s the HD frequency had increased to 3HD/ week [7] . Incredibly, the 3HD/week schedule has been widely accepted worldwide without ever undergoing any randomized controlled trial (RCT) to examine whether less frequent HD treatments would be inadequate or harmful [8] .
The optimal regimen for incident patients is not known. However, it is plausible that the routine practice of fixed-dose 3HD/week in incident patients with substantial RKF may be harmful, contributing to accelerated loss of RKF [9, 10] .
Incremental HD is based on the simple idea of adjusting its dose according to the metrics of RKF. In agreement with the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, the term 'incremental HD' implies that the dose and/or frequency of treatment can be lower at dialysis inception, in the presence of a substantial RKF, but should be progressively and timely increased to compensate for any subsequent reduction in RKF [11] .
In order to quantify the amount of dialysis needed to replace the renal losses, the first problem to solve was how to compare the intermittent dialysis clearance with the continuous RKF. The above guidelines, which notably were developed in the context of peritoneal dialysis (PD), where the near-continuous nature of peritoneal clearance (Kp) makes it look like RKF, solved the problem by just assuming the clinical equivalence between urea Kp and residual renal urea clearance (Kru) [11] . On this basis, the KDOQI guidelines could establish the principle of the constancy of the total (dialytic þ renal) clearance, as expressed by the weekly fractional urea clearance (Kt/V): for any amount lost in Kru, an equivalent amount of Kp should be increased, so that the total weekly Kt/V could remain at least equal to 2.0, which was the adequate level for continuous ambulatory PD (CAPD) patients at that time [11] .
The first KDOQI guidelines on PD adequacy extended the concept of clinical equivalence between renal and dialysis clearance, already hypothesized for PD, to the HD, with the associated rule of the constancy of the total clearance [11] .
The total Kt/V Historically, the approach of transforming the continuous Kru into an intermittent dialysis dose was introduced by Gotch and Keen in 1985 [12] : soon after the introduction of the Kt/V as an expression of dialysis dose [13] , he introduced also the concept of total fractional urea clearance (KT/V), computed as follows:
where Kt/V is the dialytic fractional urea clearance, k Â Kru/V is the intermittent equivalent of continuous Kru, V is the urea distribution volume (L) and k is the coefficient value that transforms Kru/V into Kt/V units (9.5 in the case of a 2HD/week regimen and 5.5 in the case of a 3HD/week regimen) [12] .
The equivalent continuous clearance
The concept of the equivalent continuous clearance (ECC), which transforms the intermittent clearance into a continuous one, was introduced by Casino and Lopez in 1996 [14] . They named the new parameter of the standard urea kinetic model (UKM) 'equivalent renal clearance' (EKR), to be computed as the G/TAC ratio, in which G is the urea generation rate (G) and TAC is the time-averaged concentration of blood urea nitrogen (BUN) concentration in HD patients. Of note, EKR, depending on TAC, which in turn depends on both Kru and the dialyser urea clearance (Kd), expresses a total clearance. In order to isolate the contribution of dialysis to EKR (EKRd), one has to compute EKR and then subtract Kru from EKR [14] . Moreover, EKR should be normalized to V to allow comparison among patients with different V values. However, to get units of millilitres per minute, which are clinically more attractive, Casino and Lopez suggested correcting EKR by multiplying EKR/V times a typical V of 40 L (EKRc). Such a correction for a reference V is analogous to that of creatinine clearance (CrCl) for the standard body surface area (BSA) of 1.73 m 2 : in fact, one has to divide CrCl by BSA and multiply it by 1.73 m 2 [14] . An analogous correction was suggested for Kru: [14] . Of note, recently, the reference V has been changed to 35 L, because Kru expressed per V ¼ 35 L is numerically very similar to Kru expressed per 1.73 m 2 [15] . Accordingly, EKRc and Krc have been renamed as 'EKRc 35 ' and 'Krc 35 ', respectively [15] . Herein, we acknowledge that EKR and its related parameters can reliably be computed with 'Solute-Solver' [16] , a software freely available at www.ureakinetics.org, and recommended by the 2015
Update of the KDOQI guidelines as a reference tool for double pool urea modelling [17] . Furthermore, for the sake of uniformity to the Solute-Solver symbols and abbreviations, we are adding here a 'U' to the above parameters, so that, EKR and Kr become EKRU and KRU, respectively; moreover, the 'corrected' parameters EKRc and EKRc 35 become the 'normalized' EKRUn. Analogously, Krc and Krc 35 are renamed as 'normalized KRU' (KRUn).
The concept of the ECC was accepted by Gotch [18] , who, in agreement with the so-called 'peak concentration hypothesis' [19] , suggesting that uraemic toxicity could be related to peak concentration rather than TAC, introduced the concept of standard clearance (stdK), a new version of ECC, to be computed as the ratio of G to the pre-dialysis averaged concentration of BUN (MeanPre). The stdK seemed to reconcile the differences in Kt/V values required in HD and CAPD: in fact, the adequate stdK Â 10 080 min in a week/V (stdKt/V, v/week) in HD was 2.0, coinciding with the adequate (at that time) weekly Kt/V in CAPD [18] .
T H E C U R R E N T P R E S C R I P T I O N O F I N C R E M E N T A L H D
The comparison between renal and dialysis clearance could be based either on the total Kt/V or on one of the two current versions of ECC, namely, EKRc and stdKt/V. For each of the above indices there is a specific target that guides the modelling of incremental HD. However, more recently the total Kt/V is being used less and less, so we will concentrate on the prescription based only on the more popular EKRc and stdKt/V indices.
The prescription based on the EKRc
By using the variable volume single-pool UKM [20] , Casino and Lopez found that an anuric patient receiving a Kt/V of 1.0 on a 3HD/week schedule, in agreement with the dialysis adequacy criterion at that time, would have an EKRc of about 11 mL/min/40 L [14] . The above authors also suggested that EKRc, being independent from the treatment schedule and/or modality, could be used to extend the adequacy criteria, originally established for the standard 3HD/week schedule, to all schedules and modalities [14] . In other words, the EKRc value of 11 mL/min/40 L could become the unique target clearance for all schedules and modalities. The EKRc prescription is based on the classic UKM method of calculating the required value for either Kd or the session length (Td) to reach a targeted TAC with the selected treatment schedule [21] . Casino and Lopez provided also a simpler approach to incremental HD prescription, which uses equations to predict EKRd as a function of Kt/ V for different schedules [14] . The concept of EKRc and the associated equations were endorsed in 2002 by the first European Best Practice guidelines dealing with the assessment on RKF [22] during HD and the modelling of incremental HD [23] , respectively. In particular, these guidelines stated: 'In the case of significant residual renal function (Kr), the amount of therapy to be delivered with HD may be estimated with the aid of the equivalent renal urea clearance (EKR).' Of note, since these guidelines upgraded the dialysis dose adequacy to an equilibrated (i.e. post-rebound) Kt/V (eKt/V) of 1.2 [24] , the adequate EKRc level was recalculated to 13 mL/min, according to the relationship:
The prescription based on the weekly Kt/V and stdKt/V Before discussing the current prescription based on stdKt/V, it could be interesting to note that the first KDOQI guidelines established the weekly Kt/V as the reference index to guide the incremental approach for both PD and HD [11] ; however, later, the stdKt/V replaced the weekly Kt/V in HD patients [18] . One should realize that the two indices are actually fairly similar, at least as far as the incremental dialysis is concerned. In fact, 'the fundamental assumption underlying CAPD, that at the same protein catabolic rate (nPCR), continuous renal replacement therapy must keep the steady state BUN equal to the average pre-haemodialysis BUN' [11] , also means that a CAPD patient with a given G and a given steady state BUN, has the same clearance as a HD patient with the same G and MeanPre equal to the above BUN. This coincides with the definition of stdK ¼ G/MeanPre ¼ G/BUN [18] .
As discussed above, the EKR concept, expressed by the ratio G/TAC [14] , was subsequently modified by Gotch, who introduced the concept of stdK, where TAC was replaced by MeanPre [18] . By noting that EKR ¼ G/TAC and TAC is about 70% of MeanPre, it follows that stdK is about 70% of EKR. By multiplying stdK Â 10 080/V, one gets the stdKt/V that, as stated by Gotch, would provide 'a uniform expression of the dose of dialysis as an equivalent, normalized continuous clearance for all combinations of intermittent and continuous treatment modalities' [18] . Obviously, stdKt/V would be 70% of an analogous EKR-based Kt/V, i.e. EKR Â 10 080/V. One of the strengths of the stdKt/V was that it seemed to reconcile adequacy on HD and CAPD: in fact, an adequate eKt/V of 1.05 on a 3HD/week schedule would correspond to a stdKt/V of 2.0, as would be the case for a weekly Kt/V of 2.0 on CAPD.
More recently, however, such a key feature of stdKt/V, i.e. the coincidence of HD adequacy as established by stdKt/ V ¼ 2.0 on HD with a weekly Kt/V ¼ 2.0 on CAPD, was not confirmed: mainly due to the results of two RCTs in CAPD patients [25, 26] , the 2006 update of KDOQI guidelines [27] had to admit that 'the minimally acceptable small-solute clearance for PD is less than the prior recommended level of a weekly Kt/ Vurea of 2.0. Furthermore, increasing evidence indicates the importance of RKF as opposed to peritoneal small-solute clearance with respect to predicting patient survival. Therefore, prior targets have been revised as indicated. The minimal 'delivered' dose of total small-solute clearance should be a total (peritoneal and kidney) Kt/Vurea of at least 1.7 per week. (B)'. This guideline, by pointing out the 'importance of renal kidney function as opposed to peritoneal solute clearance' clearly rejected the presumed equivalence between Kru and Kp, which had been a basic tenet of the first KDOQI guidelines [11] , with a key role in establishing both the first criterion to start dialysis and the modelling of incremental dialysis therapy. In contrast to the two RCTs on CAPD adequacy [25, 26] , which provided significant results and led to reduce the minimally adequate dose in PD [27] , the HEMO study did not reach any statistical significance in favour of an increase in either dialysis dose or membrane flux [6] . Therefore, the subsequent update of the KDOQI guideline on HD adequacy [28] did not change the previous minimal dose of single-pool (sp) Kt/V (spKt/V) ¼ 1.2, corresponding to an eKt/V of 1.05 for the standard 3HD/week schedule. Also, the adequate level of stdKt/V ¼ 2.0 did not change; in fact, even if it was no more coincident with the current adequate weekly Kt/V of 1.7 on CAPD, it did correspond to the adequate eKt/V ¼ 1.05 on a 3HD/week schedule. As a consequence, these guidelines endorsed the stdKt/V as the reference index for all HD schedules, with the unique minimum value of 2.0 [28]. As noted, the formal calculation of stdKt/V is done by using UKM [18] . However, Leypoldt et al. [29] 
As far as the prescription of incremental HD is concerned, the KDOQI Work Group, for practical reasons, set a cut-off Kru of 2.0 mL/min/1.73 m The recent 2015 update of the KDOQI guidelines for HD adequacy [17] essentially confirmed the key points of the previous guidelines [28]: the target spKt/V is 1.4 per session for patients on a 3HD/week schedule, with a minimum delivered spKt/V of 1.2. In patients with significant Kru, the dialysis dose may be reduced provided Kru is measured periodically to avoid inadequate dialysis. For schedules other than 3HD/week, a target stdKt/V of 2.3 is suggested, with a minimum delivered dose of 2.1 using a method of calculation that includes the contributions of ultrafiltration and RKF [17] .
However, the 2015 update of the KDOQI guidelines changed the methods to compute the stdKt/V, particularly to correct the 'compression' of Kru, as induced by the use of MeanPre instead of TAC [17] . In fact, the Work Group pointed out that 'the stdKt/V was conceived by Gotch as a method for downgrading intermittent dialyzer clearances to the equivalent of a continuous clearance by redefining clearance as the urea generation rate (G) divided by the average predialysis BUN (avCpre)'; however, 'when measured using modeled values for G, eKt/V, and avCpre, the contribution of Kru is inappropriately downgraded because G/avCpre assumes that the Kru component also uses the avCpre instead of the average BUN in the denominator. To correct for this error when Kru is included, modeled values for G and V must be used to calculate stdKt/V in the absence of Kru, which can then be added as Kru *10080/V' [17] . Accordingly, the Work Group endorsed both the solute-solver as a reference method for urea modelling [16] and a new equation for the stdKt/V where Kru is added at 100% [30] . Further on, we shall use the latter version of stdKt/V.
Also unchanged with respect to the previous KDOQI guidelines [28] was the cut-off of 2.0 mL/min/1.73 m 2 below which Kru should be neglected. This also implied that only patients with Kru above this cut-off could be considered for a 2HD/ week schedule [17] .
A P A R A D I G M S H I F T I N I N C R E M E N T A L H D P R E S C R I P T I O N
As recently pointed out, there is a need for a paradigm shift in the incremental HD prescription [15] . In fact, the current paradigm that aims at maintaining a constant total ECC is based on the wrong assumption of the clinical equivalence between Kd and Kru. The subsequent paradoxical results associated with such a 'fixed target model' (FTM) can be appreciated more easily when using EKRUn than when using the stdKt/V. In fact, when considering that the adequate eKt/V of 1.2 delivered three times a week in an anuric patient corresponds to an EKRUn of about 12 mL/min/35 L, and by accepting that only the total matters, the following paradoxical conclusion can be drawn: the patient would have the same clinical outcome both if, for instance, she/he is anuric with a total EKRUn of 12 mL/min/35 L provided by dialysis only and if she/he has a KRUn of 12 mL/ min/35 L, which would allow her/him to be still maintained on conservative therapy [15] .
In order to try to account for the greater clinical importance of Kru versus Kd, Casino and Basile suggested that the target for the total clearance should vary in an inversely proportional way to RKF (the so-called 'variable target model'-VTM) [15] . In short, since most patients develop symptoms when the glomerular filtration rate (GFR) is about 6-9 mL/min/1.73 m 2 [31] , one could assume that a GFR >9 mL/min/1.73 m 2 does not require any dialysis. Such a GFR corresponds roughly to a KRU of 6 mL/min/1.73 m 2 : in fact, in uraemic patients, as an average, GFR ¼ (KRU þ CrCl)/2 and CrCl ¼ 2 Â KRU. On the other hand, in anuric patients, the adequate dialysis clearance value of 12 mL/min/1.73 m 2 should be provided. Thus, the total clearance (EKRUn) varies by 6 units, from 6 to 12 mL/minper 1.73 m 2 or per 35 L, when KRUn varies by 6 units, from 6 to 0 mL/min/35 L, i.e. it increases by 1 mL/min/35 L per each mL/ min/35 L lost by KRUn. This also means that the maximum target of 12 mL/min/35 L in anuria decreases by 1 mL/min/35 L per each mL/min/35 L increase in KRUn. Thus, the equation predicting the variable target for EKRUn is: VT-EKRUn ¼ 12 À KRUn. In contrast, the equation predicting the fixed target is: FT-EKRUn ¼ 12 mL/min/35 L. At the same time, the needed dialyser clearance varies by 12 units, from 0 at KRUn ¼ 6 mL/ min/35 L to 12 mL/min/35 L in anuria, when KRUn varies by 6 units, from 6 to 0 mL/min/35 L, i.e. it increases by 2 mL/min/ 35 L per each mL/min/35 L lost by KRUn. In other words, KRUn weights clinically two times the dialyser clearance, expressed as the normalized dialyser urea clearance, i.e. the dialysis component of the normalized total ECC (EKRUd ¼ EKRUn À KRUn). Interestingly, the reduction in the target for the total clearance can also be seen as a 'compression' of the normalized dialyser clearance (J. T. Daugirdas, personal communication); in fact, the VTM leads to increase in the relative weight of Kru by a 1:2 ratio. This means that 1 mL/min of Kru should be replaced by 2 mL/min of dialysis clearance. The latter can be seen as being 'compressed' by 50%. Accordingly, a total 'effective' clearance could be obtained by summing the 'compressed' dialysis clearance to the actual KRU. This is just what happens with the total stdKt/V, which is obtained by summing the actual Kru at 100% to the compressed dialysis stdKt/V. This explains the similarities found by Casino and Basile between the 'adequacy lines' associated with VT-EKRU ¼ 12 À Kru and stdKt/ V ¼ 2.3, respectively [15] . The two indices, however, differ in many aspects. The first one is the critical KRUn value, which is 6 mL/min/35 L for VTM and 8 mL/min/35 L (2.3 Â 35 000/ 10 080) for stdKt/V. The second one is the degree of compression of the dialysis clearance, which is at 50% for VT-EKRU, but only at 33% with stdKt/V. In fact, usually, the TAC/ MeanPre ratio is $67%, so that stdK is 67% of EKRU, i.e. it is compressed by 33%. A useful differential feature of VTM, particularly in view of preparing an RCT, is that it is not intrinsically bound to the current value for the critical KRUn level of 6 mL/min/35 L, or to the current maximum target of 12 mL/ min/35 L. In fact, by assuming, for instance, a critical KRUn of 4 mL/min/35 L (corresponding to a GFR of about 6 mL/min/ 1.73 m 2 ) one could find a new KRUn to normalized dialyser ratio of 4/12 ¼ 1:3, further increasing the clinical weight of KRU, or the compression of the dialysis clearance. As a further example, one could also reduce the maximum EKRUn from 12 to 10 mL/min/35 L (corresponding to an eKt/V of about 1.05), and find a ratio of 4/10 ¼ 1:2.5.
By using the 'Solute-Solver' software [16] , Casino and Basile computed eKt/V values to be prescribed to attain either the fixed or the variable target EKRc 35 for Kru varying from 0 to 5.0 mL/min/1.73 m 2 , and for one, two and three HD sessions per week [15] . Actually, they provided many graphs showing the relationship between eKt/V and Kru for fixed and variable targets not only of EKRc 35 but also of stdKt/V. Clearly, only when using the reference UKM one can get accurate results; however, these graphs provide an estimate of eKt/V that should suffice for clinical uses [15] .
THE UKM IS THE KEYSTONE FOR C O N D U C T I N G A N R C T O N I N C R E M E N T A L H D
The recently heightened interest in incremental HD [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] has been hindered by the current UKM-based prescription that, by overestimating the dialysis needs, in the presence of substantial RKF, would require such high values for both the RKF and dialysis dose (Kt/V) [15] that it would be difficult to prescribe less frequent treatments. This could cast doubts on the usefulness of the UKM as a guide to the prescription of incremental HD and push the search for alternative indices of dialysis adequacy. While agreeing that evaluating the dialysis adequacy should not rely on a single index, we would like to remark on the need to keep UKM as the gold standard, not only because it is the only established tool for assessing and prescribing dialysis [17, 20, 23] , but mostly because we have to realize that it is not responsible for the overestimation of dialysis needs. The problem is not intrinsic to the UKM, but rather is generated by a misconception or rather misunderstanding, i.e. the equivalence between Kru and Kd, correctly assumed by the UKM, only means that each millilitre per minute of Kd clears the urea from the blood just as 1 mL/min of Kru does [14, 17] . By no means should such kinetic equivalence imply that 1 mL/min of Kd is clinically equivalent to 1 mL/min of urea clearance provided by the native kidneys.
Therefore, an RCT comparing incremental HD with the standard 3HD/week schedule and focused on hard outcomes, such as survival and health-related quality of life of patients, is urgently needed. It is also clearly evident that the group of patients mostly benefited by a hypothesized advantage of incremental HD would be that of elderly patients, whose incidence and prevalence in the dialysis population is constantly growing worldwide. As said, the recent paper by Casino and Basile suggested that the VTM, which gives more clinical weight to the RKF, allows less frequent HD treatments at lower RKF as opposed to the FTM, based on the wrong concept of the clinical equivalence between Kru and Kd [15] . To test the VTM hypothesis, an RCT should be planned in incident HD patients: one arm would enroll patients starting either on standard 3HD/week or incremental HD aiming at the constant EKRUn target of 12; the other arm would enroll patients starting on incremental HD using either EKRUn with the variable target of 12 À KRUn, or stdKt/V with the constant target of 2.3.
The first step in designing such a study is to compute the 'adequacy lines' and the associated fitting equations necessary for the most appropriate allocation of the patients in the two arms and their correct and safe follow-up. Actually, we refined the 'adequacy lines' and the associated fitting equations already published [15] , by extending the considered intervals for both KRU and eKt/V, and using more realistic ultrafiltration rate values. In particular, we have assumed a V of 35 L and computed the three eKt/V values required to attain the three different targets, respectively, for different KRU values and schedules, namely: FT-EKRU ¼ 12, VT-EKRU ¼ 12 À KRU and stdKt/ V ¼ 2.3. By considering that the incremental HD can be prescribed only in the presence of a significant RKF, which is associated with a significant urine output (UO) [45] , we have used a very low weekly weight gain (2.0 kg/week) for once-weekly schedules, a low weekly weight gain (4.0 kg/week) for twiceweekly schedules and finally, a weekly weight gain of 6.0 kg/ week, that could reasonably be obtained in the presence of some residual UO, for thrice-weekly schedules. Of note, since the rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality [46] , the 'adequacy' issue of ultrafiltration rate deserves particular attention in the management of incremental HD. For instance, Kalantar-Zadeh et al. [3] suggested the need for a UO of at least 500 mL/day and the presence of only a 'limited fluid retention', i.e. an inter-dialytic weight gain (IDWG)<2.5 kg (or <5% of ideal dry weight) without HD for 3-4 days, as a first and second criterion, respectively, to initiate and maintain a twice-weekly HD. In practical terms, the monitoring of incremental HD requires a frequent assessment of UO and KRU; however, the key assessment is the day-by-day analysis of the IDWG trend, because any rapid major increase in IDWG can give the clue about a worsening RKF and the associated need for increasing the dose and/or frequency of dialysis.
The eKt/V to be prescribed to attain the desired target in the three different dialysis schedules can be read easily and quickly (Figures 1-3) . Each figure has three traces, the first one for FT-EKRU, the second one for stdKt/V and the third one for VT- Clinical trial for incremental haemodialysis EKRU. The fitting coefficients for each line, within the intervals shown in the figures, are given in Table 1 . The graphs and the fitting equations allow a rapid calculation of the dialysis dose to be prescribed to attain the desired target. As said, since in these simulations V ¼ 35 L, KRU and EKRU coincide with KRUn and EKRUn. The figures also allow an easy comparison among the dialysis needs with the three different approaches, for example: at a KRU of 3.0, on a 3HD/week schedule, the FTM predicts the need for an eKt/V of 0.94, whereas it is only 0.62 with the VTM (Figure 1) ; and on a 2HD/week schedule, the needed eKt/V is 1.58 with the FTM and only 0.95 with the VTM (Figure 2) . Figure 3 shows that, on once-weekly HD, the FTM would require KRU>7.5 and eKt/V >1.6, whereas for the VTM a KRU>3.8-4.0 could suffice. As already published [15] , the above graphs also show that the patterns of 'adequacy lines' for VTM-EKRU and for stdKt/V ¼ 2.3 are similar: almost overlapping in Figure 1 , and running in a parallel way, with a difference of about 0.2 eKt/V units, in Figure 2 . The lines also run in a parallel way in the 1HD/week schedule (Figure 3 ), but the associated eKt/V, due to the steep slope, are quite different: for example, for KRU ¼ 5.0, the needed eKt/V is 1.61 with stdKt/V, and only 0.61 with VTM-EKRU.
Finally, our long-term experience in the field allows us to give some practical advice: the current target of 2.3 v/w of the stdKt/V could already allow a wider use of the twice-weekly HD schedule. Clearly, the Kru and UO as well as the metabolic and clinical conditions should be assessed with increased frequency. Furthermore, since the targets are about 10-15% higher than the minimum required values, there is no need to aim at ECC values higher than the target [47] . Our empirical observations [47] are in agreement with some recent literature data, showing that an excessive amount of dialysis could lead to a faster loss of RKF [9, 32] . This should be kept in mind when we are faced with a patient with elevated BUN levels who has to start dialysis; some sort of conditioned reflex leads many clinicians to start with an intensive dialysis programme, which could cause an irreversible reduction in kidney function, just as an aggressive ultrafiltration rate could do.
C O N C L U S I O N S
The recently heightened interest in incremental HD has been hindered by the current limitations of the UKM, which tend to overestimate the needed dialysis dose in the presence of a substantial RKF. A recent paper by Casino and Basile suggested a VTM, which gives more clinical weight to the RKF and allows less frequent HD treatments at lower RKF as opposed to the FTM, based on the wrong concept of the clinical equivalence between Kru and Kd [15] . An RCT enrolling incident patients and comparing incremental HD (prescribed according to the VTM) with the standard 3HD/week schedule and focused on hard outcomes, such as survival and health-related quality of life of patients, is urgently needed.
In conclusion, the potentially important clinical and financial implications of the incremental HD render it highly promising and warrant RCTs. The UKM is the keystone for conducting such studies.
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